Company profile: Arbutus Biopharma
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies for hepatitis B virus (HBV), including Imdusiran (AB-729), a subcutaneously delivered RNAi therapeutic designed to reduce HBV viral antigens such as HBsAg, and AB-101, an oral PD-L1 inhibitor intended to reawaken HBV-specific T cells by blocking the PD-1/PD-L1 protein-protein interaction.
Products and services
- AB-101: An oral PD-L1 inhibitor intended to reawaken HBV-specific T-cells by blocking the PD-1/PD-L1 protein-protein interaction to promote T-cell activity against HBV
- Imdusiran (AB-729): A subcutaneously-delivered RNAi therapeutic engineered to reduce all HBV viral antigens, including HBsAg, achieving broad antigen suppression via RNA interference
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Arbutus Biopharma
OM Pharma
HQ: Switzerland
Website
- Description: Provider of microbial-derived immunotherapeutic products addressing acute and chronic immunological disorders from infections and inflammation, operating worldwide through partners and investing in R&D. Products include Broncho-Vaxom to regulate the immune system and prevent recurrent respiratory infections, Uro-Vaxom to treat and prevent recurrent lower urinary tract infections, and Dicynone for capillary hemorrhage prevention and treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OM Pharma company profile →
Tetraphase Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics for significant disease categories, including GIAPREZA to increase blood pressure in adults with septic or other distributive shock; XERAVA for complicated intra-abdominal infections in adults; XACDURO for hospital- and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter baumannii-calcoaceticus complex; and investigational zoliflodacin for uncomplicated gonorrhea.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tetraphase Pharmaceuticals company profile →
Iterum Therapeutics
HQ: Ireland
Website
- Description: Provider of clinical-stage anti-infectives targeting multi-drug resistant pathogens. Offers sulopenem, an oral and IV penem antibiotic with broad-spectrum activity against multi-drug resistant gram-negative infections in hospital and community settings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iterum Therapeutics company profile →
Calimmune
HQ: United States
Website
- Description: Provider of clinical-stage gene therapies, including a lead gene-based therapeutic candidate engineered to control HIV infection and protect individuals with HIV from progressing to AIDS. The therapy is currently being evaluated in Phase I/II studies. Cal-1 is designed to reduce production of CCR5, a protein.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calimmune company profile →
Bugworks Research
HQ: India
Website
- Description: Provider of drug discovery focused on combating antimicrobial resistance (AMR) and small molecule cancer therapeutics, including BWC2094 targeting the adenosine pathway (CRC, NSCLC, TNBC, pancreas, prostate, RCC, HNSCC); ATM/DNA-PK dual inhibitors (BWC5036/BWC5089); BWC5044/BWC5077, BWC4496; spliceosome modulators/DNA damage agents; and ADC payload opportunities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bugworks Research company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Arbutus Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Arbutus Biopharma
2.2 - Growth funds investing in similar companies to Arbutus Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Arbutus Biopharma
4.2 - Public trading comparable groups for Arbutus Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →